atrial fibrillation
Conditions
Interventions
Experimental group :dagliflozin 10mg qd
control group:placebo
Sponsors
Department of Cardiology, Shanghai Changhai Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. symptomatic nonvalvular atrial fibrillation with an episode of atrial fibrillation confirmed by electrocardiogram, ambulatory electrocardiogram, or randomized electrocardiogram evidence at the time of symptom presentation 2. failure of treatment with at least one class III antiarrhythmic drug or patient intolerance 3. age 18-85 years 4. the patient understands the advantages and disadvantages of cryoablation and radiofrequency ablation. 5. the subject or legal representative understands and is willing to sign an informed consent form to participate in the trial.
Exclusion criteria
Exclusion criteria: 1. Thrombosis in the left atrium or left auricle 2. Left atrial anteroposterior diameter >50mm 3. High risk of bleeding or contraindication to anticoagulant use. 4. Stroke or myocardial infarction within 3 months. 5. uncontrolled hyperthyroidism 6. pregnancy 7. Expected survival <1 year 8. eGFR < 60 ml/min 9 Refusal to participate in this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence of atrial arrhythmias on days 91-365 after catheter ablation of atrial fibrillation;1-year atrial arrhythmia burden after atrial fibrillation catheter ablation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of patient symptoms;Patient readmission rate within 1 year;Patient medical expenses; | — |
Countries
China
Contacts
Public ContactGUO ZHIFU
Shanghai changhai hospital
Outcome results
None listed